Professor Andrew McLachlan
BPharm, PhD, FPS, FACP, MCPA, MSHPA
Professor of Pharmacy (Aged Care)
Program Director, NHMRC Centre for Research Excellence in Medicines and Ageing
A15 - Pharmacy And Bank Building
The University of Sydney
|Telephone||+61 2 9351 4452; Concord +61 2 9767 7373|
|Fax||+61 2 9351 6950|
Professor Andrew McLachlan is the Program Director of the NHMRC Centre for Research Excellence in Medicines and Ageing, and leader of Health Services and Patient Safety Research theme at the Faculty of Pharmacy and at Concord Hospital’s Centre for Education and Research on Ageing. He is a pharmacist, academic and researcher experienced in clinical and experimental pharmacology and research on the quality use of medicines. His research focuses on understanding the variability in response to medicines and how this can be managed to optimise patient care, particularly in special patient populations such as older people, the very young and the critically ill. He is interested in translating clinical pharmacology research into real-world practice. A key collaboration is the creation and maintenance of an herb-drug interactions database for healthcare professionals, which to date includes >700 monographs. He collaborated on the SEARCH-AF study, which demonstrated the feasibility and cost-effectiveness of an iPhone ECG App for community screening of atrial fibrillation in pharmacies, and was co-author with researchers from the George Institute for Global Health on a study published in the Lancet (2014), which found that paracetamol was no more effective than placebo for improving the time to recovery in people with acute low back pain. Professor MacLachlan is Chair of the Sydney Local Health District Human Research Ethics Committee and the Drug and Therapeutics Committee, an Advisory Committee Member of the Ageing and Alzheimer’s Institute at Concord Hospital, and past President of the Australasian Pharmaceutical Science Association (APSA). He has served on expert panels advising the Therapeutic Goods Administration on medicines and the Australian Government on antidoping, and was appointed the inaugural Chair of the National Medicines Policy Committee (2009-2013) by the Minister for Health and Ageing. He was awarded Pharmacist of the Year (2006) by the Pharmaceutical Society of Australia, and received the 2013 Australasian Pharmaceutical Science Association APSA medal, the association’s highest award. He is an Executive Editor of the British Journal of Clinical Pharmacology.
Professor McLachlan’s research covers the following areas:
The impact of ageing on drug disposition and response to medicines.
Includes clinical pharmacological studies in older people, assessing the manner in which age affects response to medicines, age-related patterns of using medications, and how these factors inform the quality use of medicines. Currently he is involved in a trial of deprescribing (i.e. judicious and appropriate cessation of) medications in older individuals.
Ethnic differences in drug response.
Collaborations with GSK studying the impact of geographical ancestry on the response to medicines, to help inform the safe use of medications and new drug development.
Investigates the impact of herbal medicines on conventional medicines including insights related to the mechanism and consequences of these interactions.
Therapeutic drug monitoring as a tool for optimised drug therapy.
Current research focuses on antifungal treatments, aiming to individualise and guide optimal pharmacological endpoints by accounting for individual variability in response to these medications.
Optimal anticoagulant use in older people.
Includes the development and assessment of a collaborative model of home-based post-discharge warfarin management service, which was associated with a significantly reduced rate of readmissions and adverse events and improved persistence with therapy, and studies of herb-drug interactions with warfarin.
Optimal treatment of low back pain.
Series of collaborations on the efficacy of various interventions including physiotherapy, NSAIDs and paracetamol in low back pain, which led to two publications in the Lancet (2007 and 2014). The research is now being extended to explore interventions in the management of sciatica and in defining the management model that best serves patients with acute low back pain in the primary care setting.
- Optimising anticancer therapies by understanding pharmacokinetic and pharmacodynamic variability.
Quality use of medicines.
Including the patterns of medicines use and how this relates to quality care and health outcomes in the area of mental health, cardiovascular disease and cancer.
- Quality and safety in medication management.
Teaching and supervision
Undergraduate and postgraduate teaching in pharmacy and medicine including clinical pharmacology, pharmacokinetics and pharmacodynamics, hepatic disease, aged care, experiential placements in the hospital setting.
PHAR 5512 – Clinical Residency 2 (Coordinator)
PHAR 7112 - Healthy Ageing Pharmacy Practice (Coordinator)
Current research students
|Project title||Research student|
|Patient Centred Antimicrobial Stewardship||Fiona DOUKAS|
|Ethnic differences in response to anticancer agents||Josephine TOUMA|
Editorial Board Membership
British Journal of Clinical Pharmacology (Executive Editor, 2008 - ongoing)
Journal of Pharmacy Practice and Research (Associate Editor, 2007 - ongoing)
Journal of Pharmacokinetics and Pharmacodynamics (2006-2009)
Journal of Pharmacy and Pharmacology (2004-2008)
Drug Information Journal (2003-2008)
Australian Medicines Handbook (2001 - 2011)
Australian Medicines Handbook, Aged Care Companion (2003, 2006, 2014)
Australian Pharmaceutical Formulary and Handbook (2000-2015) APF 17, APF 18, APF 19, APF 20, APF 21, APF 22 and APF 23.
Associate Dean (Research), Faculty of Pharmacy (2010 - 2012)
Member, SEG-Research Committee, University of Sydney (2010 - 2012)
Chair, Postgraduate Coursework Subcommittee and Deputy Chair, Combined Board of Postgraduate Studies in Dentistry, Medicine and Pharmacy (2000-2008)
Director (Clinical Studies), Herbal Medicines Research and Education Centre, University of Sydney (2003 - 2011)
Associate Dean (Postgraduate) and Chair, Postgraduate Committee, Faculty of Pharmacy (2000-2005)
Hospital Service Member (and now Chair), Sydney Local Health District – Concord Hospital, Human Research Ethics Committee (2007 - ongoing)
Member, Drug and Therapeutics Committee, Concord Hospital (2006 – ongoing)
Professional & Community Contributions
Chair, National Medicines Policy Committee, Department of Health, Australian Government (2009 - 2012)
Member, National Medicines Policy Executive, Department of Health, Australian Government (2009 - 2012)
President (2009-2012) and Councilor (2006 – 2009), Australasian Pharmaceutical Science Association (APSA)
Member (and now Chair), Pharmaceutical Subcommittee, Advisory Committee on Prescription Medicines, Therapeutic Goods Administration (2002 - ongoing)
Member, Australian Therapeutic Goods Advisory Council (2012 – ongoing)
Member (and now Chair), Anti-Doping Rule Violation Panel, Department of Health, Australian Government (2010 – ongoing)
Member, Medication Reference Group, Australian Commission on Safety and Quality in Healthcare (ACSQHC) (2010 – ongoing)
Board Member, ANZAC Medical Research Institute (2014 – ongoing)
Member, NHMRC Assigners Academy (2014-2015)
Member, NHMRC Pharmacology/Respiratory Grant Review Panel (2006- 2013)
Panel Chair, NHMRC Postdoctoral Training Grants (2004-2006)
Awards and honours
Australasian Pharmaceutical Science Association APSA medal (2013)
Pharmaceutical Society of Australia, Pharmacist of the Year (2006)
Vice-Chancellor’s Award for Outstanding Teaching – awarded jointly (2001)
The University of Sydney Medal (Pharmaceutics) (1987)
Pharmaceutical Society Pharmacy Gold Medal (1986)
Clinical pharmacology; Mental health; Ageing; Cardiovascular diseases
- The Agilent 6470 Triple Quadrupole LC/MS System; Witting P, McLachlan A, Hunter D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
- From ‘BIG DATA’ to evidence: Post-market surveillance of psychotropic medicines in Australia; Schneider C, Pearson S, Karanges E, McGregor I, Buckley N, McLachlan A, Wilson F, Marshall N, Hunt G, Allsop D, Bowen M, Hunt C, Russell J, Abbott M, Lintzeris N; DVC Research/HMR+ Implementation Fund - University.
- Cognitive ageing in cancer populations: a cohort study extension in colorectal cancer survivors; McLachlan A, Dhillon H, Vardy J, Waite L, Lagopoulos J, Mackenzie L, Johnston I, Clarke S, Cysique L; DVC Research/SPARC Implementation - Cancer.
- Patient-centred eHealth approach to improving outcomes for gout sufferers; Laba T, McLachlan A; National Health and Medical Research Council (NHMRC)/Partnership Projects.
- The first placebo-controlled trial of opioid analgesics for acute spinal pain; Lin C, Maher C, McLachlan A, Latimer J, Billot L, Koes B; National Health and Medical Research Council (NHMRC)/Project Grants.
- Phase 1 clinical trial: Inhaled rifapentine for rapid treatment of tuberculosis; Chan K, McLachlan A, Chan J, Parumasivam T; Rebecca L Cooper Medical Research Foundation/Equipment Grant.
- EVOS FL Auto cell imaging system; Nicholson G, Clark G, Zhou H, Jessup W, Le Couteur D, McMahon A, McLachlan A, Allan C, Handelsman D, Hart D, Walters K, Kritharides L, Kockx M, Kennerson M, Cooper M, Seibel M, Verma N, Silveira P, Fromm P, Simanainen U, Cogger V, Zheng Y; National Health and Medical Research Council (NHMRC)/Equipment Grants.
- Centre of Research Excellence in Medicines and Ageing; McLachlan A, Pearson S, Banks E, Preen D, Le Couteur D, Dobbins T, Etherton-Beer C, Buckley N, Viney R, Henry D; National Health and Medical Research Council (NHMRC)/Centres for Research Excellence.
- Pregabalin in addition to usual care for sciatica (PRECISE): a randomised, placebo-controlled trial; Lin C, Maher C, McLachlan A, Latimer J, Koes B, Hancock M, Harris I; National Health and Medical Research Council (NHMRC)/Project Grants.
- Patterns of care and health outcomes: Opportunities for epidemiology and health services research using whole of population, cross-jurisdictional linkage of routinely collected data; Aranda S, Buckley N, Currow D, McLachlan A, Pearson S, Young J, Armstrong B, O'Connell D, Pearson S, Le Couteur D, Buckley N; National Health and Medical Research Council (NHMRC)/Equipment Grants.
- A randomised controlled trial of deprescribing to optimise medical therapy for frail older people: the Opti-Med study; Hilmer S, Naganathan V, McLachlan A, Comans T, Etherton-Beer C, Potter K; National Health and Medical Research Council (NHMRC)/Project Grants.
- Teaching Academic; McLachlan A; Concord Hospital/Research Support.
- High risk prescribing in older Australians; Banks E, Le Couteur D, Pearson S, McLachlan A, Viney R, Hilmer S, Gnjidic D, Blyth F; National Health and Medical Research Council (NHMRC)/Project Grants.
- Regulation and authentication of scheduled and toxic Chinese herbs in Australia; Poon J, Li G, Chan K, Roufogalis B, McLachlan A, Li K, Razmovski-Naumovski V; University of Sydney/Research Support.
- Improving the use of chemotherapy by targeting the inflammatory response; Clarke S, Robertson G, Piquette-Miller M, McLachlan A, Baker M, Katsifis A; National Health and Medical Research Council (NHMRC)/Project Grants.
- Lessors Learned Form Reporting Dispensing near Miss Incidents in Community Pharmacy; Fois R, Chen T, McLachlan A; Pharmaceutical Defence Limited (PDL)/Research Grant.
- Organic anion transporting polypeptide 1A2 pharmocogenetcs in the determination of personalized treatment protocols with imatinib; Zhou F, Murray M, McLachlan A; Pharmacy Research Trust of NSW/Research Support.
- RES: Updating information contained in The University of Sydney, Herb-Drug Interaction Database (2013-044); McLachlan A, Duke C, Roufogalis B; UnityHealth Pty Ltd/Research Support.
- Optimising pain management in frail older people; McLachlan A, Naganathan V, Le Couteur D, Hilmer S, Gibson S; National Health and Medical Research Council (NHMRC)/Project Grants.
- Development of personalised dosage protocols for tyrosine kinase inhibitors in oncology patients; Murray M, Gurney H, McLachlan A; Cancer Council New South Wales/Research Project Grants.
- The first placebo-controlled trial of paracetamol for back pain; Latimer J, Maher C, McLachlan A, Day R, Cooper C, Hancock M; National Health and Medical Research Council (NHMRC)/Project Grants.
- Optimising pain management in the frail older people; McLachlan A; University of Sydney/Bridging Support.
- Inter-Ethnic Differences in Tolerance of Anti-Cancer drugs; Clarke S, McLachlan A; National Health and Medical Research Council (NHMRC)/Project Grants.
- Quality Indicators for Best Practice Approaches to Experiential Placements in Pharmacy programs.; Hotham L, Davey A, McLachlan A, Brien J, Chaar B, March G, McAteer S, Stupans I; Australian Learning and Teaching Council Limited(ALTC)/Discipline Initiative Grant.
- A clinical trial of manipulative therapy and/or NSAIDs for significant acute low back pain; Maher C, Latimer J, McLachlan A, Cooper C; National Health and Medical Research Council (NHMRC)/Project Grants.
- A community pharmacy based anticoalgulant management service; McLachlan A, Krass I, Chen T; Pharmacy Guild of Australia/Research Grant.
- Interactions between herbal medicines and the anticoagulant warfarin; Ammit A, Duke C, McLachlan A, Roufogalis B; National Health and Medical Research Council (NHMRC)/Project Grants.
- The effects of ageing on cancer chemotherapy; Rivory L, Clarke S, McLachlan A; National Health and Medical Research Council (NHMRC)/Project Grants.